DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis

Journal Article · · American Journal of Physiology-Renal Physiology
 [1];  [1];  [1];  [1];  [2];  [3];  [4];  [5];  [6];  [7];  [2];  [8]
  1. Univ. of California, Davis, CA (United States). Division of Nephrology, Dept. of Internal Medicine
  2. Univ. of Kansas, Lawrence, KS (United States). Medical Center, Kidney Inst., Dept. of Internal Medicine
  3. Division of Nephrology, Department of Medicine, Washington University, St. Louis, Missouri
  4. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
  5. Washington Univ., St. Louis, MO (United States). Division of Nephrology, Dept. of Medicine
  6. Univ. of California, Davis, CA (United States). Dept. of Pathology
  7. Univ. of California, Davis, CA (United States). West Coast Metabolomics Center
  8. Univ. of California, Davis, CA (United States). Division of Nephrology, Dept. of Internal Medicine; Univ. of California, Davis, CA (United States). Dept. of Pathology; VA Northern California Health Care System, Sacramento, CA (United States). Medical Service

Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. Here, we now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.

Research Organization:
Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
Sponsoring Organization:
USDOE National Nuclear Security Administration (NNSA)
Grant/Contract Number:
AC52-07NA27344
OSTI ID:
1502039
Report Number(s):
LLNL-JRNL--734198; 886144
Journal Information:
American Journal of Physiology-Renal Physiology, Journal Name: American Journal of Physiology-Renal Physiology Journal Issue: 6 Vol. 315; ISSN 1931-857X
Country of Publication:
United States
Language:
English

References (54)

Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase : RCC Sensitive to Arginine Deprivation via ADI journal November 2006
Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance journal July 2013
Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) journal October 2011
Proteomic analysis of AQP11-null kidney: Proximal tubular type polycystic kidney disease journal March 2018
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity journal October 2016
The Emerging Hallmarks of Cancer Metabolism journal January 2016
FGF9 and FGF20 Maintain the Stemness of Nephron Progenitors in Mice and Man journal June 2012
The microenvironmental determinants for kidney epithelial cyst morphogenesis journal April 2008
Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease journal October 2017
Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation journal December 2017
Glutamine addiction: a new therapeutic target in cancer journal August 2010
Rapid Determination of Amino Acids in Fruits of Ziziphus jujubaby Hydrophilic Interaction Ultra-High-Performance Liquid Chromatography Coupled with Triple-Quadrupole Mass Spectrometry journal March 2013
Cyst expansion and regression in a mouse model of polycystic kidney disease journal June 2013
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis journal November 2015
Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells journal January 2003
Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy journal March 2013
A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1 journal October 2007
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease journal April 2015
Metabolic reprogramming in clear cell renal cell carcinoma journal May 2017
Arginine dependence of tumor cells: targeting a chink in cancer’s armor journal April 2016
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction journal November 2008
Grade-dependent Proteomics Characterization of Kidney Cancer journal January 2009
Relations among arginine, citrulline, ornithine, and leucine kinetics in adult burn patients journal November 1995
MethPrimer: designing primers for methylation PCRs journal November 2002
Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1 journal February 2008
Conversion of Glutamate to Ornithine and Proline: Pyrroline-5-Carboxylate, a Possible Modulator of Arginine Requirements journal April 1985
Renal Arginine Metabolism journal October 2004
Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53 journal May 2017
Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation journal April 2001
HIFalpha Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing journal April 2001
pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner journal August 2016
Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells journal April 2014
Arginine synthesis from enteral glutamine in healthy adults in the fed state journal August 2011
Arginine and ornithine kinetics in severely burned patients: increased rate of arginine disposal journal March 2001
The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate journal September 2015
Ornithine metabolism in male and female rat kidney: mitochondrial expression of ornithine aminotransferase and arginase II journal April 2004
A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease journal April 2010
Kidney Tumor Biomarkers Revealed by Simultaneous Multiple Matrix Metabolomics Analysis journal May 2012
Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging journal October 2017
ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance journal April 2013
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction journal August 2013
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer journal February 2014
Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease journal June 2013
Housekeeping and tissue-specific genes in mouse tissues journal January 2007
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy journal August 2014
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). journal May 2016
Evidence Based Selection of Housekeeping Genes journal September 2007
Importance of Suitable Reference Gene Selection for Quantitative Real-Time PCR: Special Reference to Mouse Myocardial Infarction Studies journal August 2011
Ex Vivo Modeling of Chemical Synergy in Prenatal Kidney Cystogenesis journal March 2013
Arginine enzymatic deprivation and diet restriction for cancer treatment journal January 2017
Early Embryonic Renal Tubules of Wild-Type and Polycystic Kidney Disease Kidneys Respond to cAMP Stimulation with Cystic Fibrosis Transmembrane Conductance Regulator/Na + ,K + ,2Cl Co-Transporter–Dependent Cystic Dilation journal November 2006
pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner text January 2016
Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer journal August 2016
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity text January 2016

Cited By (3)